Vivos DNA appliance shows 77% of pediatric OSA patients achieve ≥50% severity reduction in peer-reviewed trial

Vivos Therapeutics, Inc.

77% of participants had ≥50% reduction in OSA severity; 93% with severe OSA reached that threshold.
17% of children achieved complete resolution of OSA; airway volume increased 67.8% on average.
Pediatric Sleep Questionnaire scores improved 31% – statistically significant.
Data published in European Journal of Pediatrics; first multicenter trial for DNA appliance in pediatric OSA.
Study provides evidence for non-surgical alternative to adenotonsillectomy, which is only 20–40% effective.

item 8.01item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.